Revision of the American Joint Committee on Cancer staging system for breast cancer.

By S. Singletary, C. Allred, P. Ashley, L. Bassett, D. Berry, K. Bland, P. Borgen, G. Clark, S. Edge, D. Hayes and 10 more. Journal of Clinical Oncology, 2002

1,247 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/6e76d098a50c7cf6fe3391fb60c9d8a4e540367e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Reis-Filho
2. Claudia Cava
3. Joseph R. Nevins
4. A. Richardson
5. Isabella Castiglioni
6. Frederick L. Baehner
7. Ian O. Ellis
8. J. Brugge

In Oncology

1. J. Reis-Filho
2. Claudia Cava
3. John N. Weinstein
4. A. Richardson
5. J. Ludwig
6. Isabella Castiglioni
7. J. Brugge
8. Gloria Bertoli

In Pathology and Forensic Medicine

1. J. Reis-Filho
2. John N. Weinstein
3. J. Ludwig
4. Frederick L. Baehner
5. Ian O. Ellis
6. K. Pantel

Citations in the corpus

• MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, background): “Some of these factors have been associated with the survival rate of patients and their clinical outcome after treatment [14].”
• Gene expression predictors of breast cancer outcomes. (2003, background): “In breast cancer, invasion into axillary lymph nodes is the most significant prognostic factor in breast cancer (1;2).”
• Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients (2014, methodology): “¶ Tumor-node-metastasis (TNM) was classified according to the revised American Joint Committee on Cancer TNM classification (23).”
• American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005, methodology): “2 mm or less, regardless of the staining technique used to identify them.(43,44)”
• A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004, methodology): “Recurrence cases were matched with AI240933 expression as biomarkers of clinical outcome, we used Receiver Operating Characteristic (ROC) analysis (Pepe, nonrecurrence cases with respect to TNM staging (Singletary et al., 2002) and tumor grade (Dalton et al.”
• Breast cancer prognostic classification in the molecular era: the role of histological grade (2010, background): “Integration of histological grade into the relevant TNM staging system has been accepted for other common epithelial tumors such as adenocarcinoma of the prostate.”
• Biomarkers in Cancer Staging, Prognosis and Treatment Selection (2005, background): “Such small clumps of cancer cells usually lack markers of proliferation and rarely induce a stromal reaction that indicates tumour implantation or growt”
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. (2003, background): “The new American Joint Committee on Cancer classification includes patients with isolated tumor cells in lymph nodes as having node-negative status.(85) This may lead to uncertainty about the proper risk category for such patients.”